

# Yanina Jansen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6378280/publications.pdf>

Version: 2024-02-01

33  
papers

987  
citations

686830

13  
h-index

476904

29  
g-index

33  
all docs

33  
docs citations

33  
times ranked

1890  
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4431-4439.	1.8	187
2	Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. <i>Annals of Oncology</i> , 2019, 30, 1154-1161.	0.6	170
3	Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. <i>Lancet Oncology</i> , The, 2017, 18, 464-472.	5.1	139
4	Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. <i>Journal of Translational Medicine</i> , 2016, 14, 95.	1.8	117
5	Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. <i>Journal of Translational Medicine</i> , 2019, 17, 303.	1.8	89
6	A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2589-2598.	2.0	44
7	Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib. <i>Melanoma Research</i> , 2015, 25, 550-554.	0.6	39
8	Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients. <i>Journal of Translational Medicine</i> , 2016, 14, 232.	1.8	27
9	A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. <i>Cancers</i> , 2021, 13, 168.	1.7	24
10	Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases. <i>ESMO Open</i> , 2019, 4, e000464.	2.0	21
11	Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy. <i>Melanoma Research</i> , 2018, 28, 65-70.	0.6	18
12	Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma. <i>Melanoma Research</i> , 2016, 26, 157-163.	0.6	16
13	Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma. <i>Melanoma Research</i> , 2019, 29, 85-88.	0.6	15
14	Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma. <i>Melanoma Research</i> , 2015, 25, 180-183.	0.6	13
15	Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure. <i>Melanoma Research</i> , 2015, 25, 68-74.	0.6	11
16	Pembrolizumab for the treatment of uveal melanoma: A case series. <i>Rare Tumors</i> , 2020, 12, 203636132097198.	0.3	8
17	Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse. <i>Cancers</i> , 2021, 13, 442.	1.7	7
18	Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO). <i>Annals of Oncology</i> , 2016, 27, vi386.	0.6	5

#	ARTICLE	IF	CITATIONS
19	A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant therapy following the resection of melanoma macrometastases (MM).. Journal of Clinical Oncology, 2019, 37, 9585-9585.	0.8	5
20	A Focused Review on Primary Graft Dysfunction after Clinical Lung Transplantation: A Multilevel Syndrome. Cells, 2022, 11, 745.	1.8	5
21	Anti-PD-1: When to Stop Treatment. Current Oncology Reports, 2022, 24, 905-915.	1.8	5
22	Single-center "real life experience" with pembrolizumab (PEMBRO) in pretreated advanced melanoma patients.. Journal of Clinical Oncology, 2016, 34, e21049-e21049.	0.8	4
23	Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression.. Journal of Clinical Oncology, 2017, 35, 9539-9539.	0.8	4
24	Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab. Annals of Oncology, 2018, 29, x7.	0.6	3
25	A Comprehensive Review on the Surgical Aspect of Lung Transplant Models in Mice and Rats. Cells, 2022, 11, 480.	1.8	3
26	3328 A randomized controlled phase II clinical trial on autologous monocyte-derived mRNA electroporated dendritic cells for stage III/IV melanoma patients who are disease-free following the local treatment of macrometastases. European Journal of Cancer, 2015, 51, S673.	1.3	2
27	A Case Report of Long-Term Survival following Hepatic Arterial Infusion of L-Folinic Acid Modulated 5-Fluorouracil Combined with Intravenous Irinotecan and Cetuximab Followed by Hepatectomy in a Patient with Initially Unresectable Colorectal Liver Metastases. Case Reports in Oncological Medicine, 2015, 2015, 1-5.	0.2	2
28	COMBI-rechallenge: a phase II clinical trial on dabrafenib plus trametinib in BRAFV600-mutant melanoma patients who previously experienced progression on BRAF(+MEK)-inhibition. Annals of Oncology, 2016, 27, vi389.	0.6	2
29	Internal herniation through the foramen of Winslow: a case report. Acta Chirurgica Belgica, 2020, 120, 136-138.	0.2	2
30	Correlation between baseline characteristics and clinical outcome of patients with pretreated advanced melanoma who received pembrolizumab (PEMBRO) in an expanded access program (EAP).. Journal of Clinical Oncology, 2016, 34, e21058-e21058.	0.8	0
31	Abstract B003: A randomized controlled phase II clinical trial on mRNA electroporated autologous dendritic cells for stage III/IV melanoma patients who are disease-free following the local treatment of macrometastases. , 2016, , .		0
32	Whole-body MRI (WB MRI) including diffusion weighted (DW) imaging for the surveillance of melanoma patients at high risk for recurrence following surgery or systemic therapy.. Journal of Clinical Oncology, 2017, 35, e21072-e21072.	0.8	0
33	Immune cell profiling of melanoma metastases from patients treated with TriMixDC-MEL dendritic cell therapy in combination with ipilimumab.. Journal of Clinical Oncology, 2017, 35, e21030-e21030.	0.8	0